AstraZeneca's biopharma president Ruud Dobber expressed confidence in the unit's growth prospects, citing upcoming drug launches and pivotal studies. The division faces headwinds from Farxiga's patent loss and the Wainua trial failure but remains on track for the 2030 revenue target.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
